ms LAURE CLARK

Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for policies that advance the use of emerging technologies, including AI in health care Advocated for reauthorization of the Rare Pediatric Disease Priority Review Voucher program Advocated for the ORPHAN Cures Act, and related language, after previous IRA mitigation initiatives Hosted a briefing on the biotech industry Discussed the Administrations health prioritie Discussed FDA's PreCheck and Commissioners National Priority Voucher Programs

Advocated for the protection of Intellectual Property rights Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences Advocated for a reformed PTAB Advocated for Section 101 reforms that provide clearer guidelines on what constitutes patentable subject matter Advocated for granting injunctions with respect to infringing conduct once a court enters a final judgement against an infringer.

Advocated to reverse a tax provision preventing businesses from deducting their R&D expenses in the same year they were incurred Advocated to amend the Internal Revenue Code of 1986 to restore the amount of the orphan drug tax credit Advocated for an increase in the SALT cap

Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products Advocated for a strong and diverse global supply chain Advocated on the difficulties of onshoring too quickly and expressed the desire to, but through proper channels Advocated against steep tariffs on pharmaceuticals, APIs, and med devices

Advocated for increased discretionary funding for HHS appropriations, including NIH, CDC, BARDA, SNS, CCBHC Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for all federally funded scientific research institutions Advocated for a continuing resolution to fund the government

Advocated for SBIR/STTR reauthorization Discussed and informed on the Biocom CA 2025 Life Science Economic Impact Report Co-hosted a briefing on SBIR/STTR reauthorization

Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for policies that advance the use of emerging technologies, including AI in health care Advocated for reauthorization of the Rare Pediatric Disease Priority Review Voucher program Advocated for the ORPHAN Cures Act, and related language, after previous IRA mitigation initiatives

Advocated for the protection of Intellectual Property rights Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences Advocated for a reformed PTAB Advocated for Section 101 reforms that provide clearer guidelines on what constitutes patentable subject matter Advocated for granting injunctions with respect to infringing conduct once a court enters a final judgement against an infringer.

Advocated for permanent adoption of the telehealth flexibilities created during the COVID-19 public health emergency Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for policies that advance the use of emerging technologies, including AI in health care Advocated for reauthorization of the Rare Pediatric Disease Priority Review Voucher program

Advocated for the protection of Intellectual Property rights Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences Advocated for a reformed PTAB Advocated for Section 101 reforms that provide clearer guidelines on what constitutes patentable subject matter

Advocated for permanent adoption of the telehealth flexibilities created during the COVID-19 public health emergency Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for policies that advance the use of emerging technologies, including AI in health care Advocated for reauthorization of the Rare Pediatric Disease Priority Review Voucher program

Advocated for the protection of Intellectual Property rights Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences Advocated for a reformed PTAB Advocated for Section 101 reforms that provide clearer guidelines on what constitutes patentable subject matter

Advocated for increased discretionary funding for HHS appropriations, including NIH, NCATS, CDC, BARDA, SNS Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for all federally funded scientific research institutions

Advocated for the expansion of the biopreferred program Advocated for the reauthorization of the Farm bill

Advocated for permanent adoption of the telehealth flexibilities created during the COVID-19 public health emergency Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated against reasonable pricing provisions in NIH awards contracts Advocated for policies that advance the use of emerging technologies, including AI in health care Advocated for the reauthorization of pandemic preparedness legislation Advocated for reauthorization of the Rare Pediatric Disease Priority Review Voucher program

Advocated for increased discretionary funding for HHS appropriations, including NIH, NCATS, CDC, BARDA, SNS Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for all federally funded scientific research institutions

Advocated for the expansion of the biopreferred program Advocated for the reauthorization of the Farm bill

Advocated to reverse a tax provision preventing businesses from deducting their R&D expenses in the same year they were incurred

Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products

Advocated for the expansion of the biopreferred program Advocated for the reauthorization of the Farm bill

Advocated to reverse a tax provision preventing businesses from deducting their R&D expenses in the same year they were incurred

Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products

Advocated for increased discretionary funding for HHS appropriations, including NIH, NCATS, CDC, BARDA, SNS Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for the VA appropriations, including the National Pharmacogenomic Program Advocated for increased discretionary funding for all federally funded scientific research institutions

Advocated for the protection of Intellectual Property rights Advocated for the protection of the Bayh-Dole Act and against using march-in provisions to control drug pricing Expressed opposition to the proposals waiving IP protections for covid-19 vaccines, diagnostics, and treatments under the TRIPS agreement. Expressed opposition to FDA and PTO collaboration activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences

Advocated for the protection of Intellectual Property rights Advocated for the protection of the Bayh-Dole Act and against using march-in provisions to control drug pricing Expressed opposition to the proposals waiving IP protections for covid-19 vaccines, diagnostics, and treatments under the TRIPS agreement. Expressed opposition to FDA and PTO collaboration activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities

Advocated to reverse a tax provision preventing businesses from deducting their R&D expenses in the same year they were incurred, including sponsoring a briefing on Capitol Hill for Congressional Staff on 10/26.

Advocated for the protection of Intellectual Property rights Advocated for the protection of the Bayh-Dole Act and against using march-in provisions to control drug pricing Expressed opposition to the proposals waiving IP protections for covid-19 vaccines, diagnostics, and treatments under the TRIPS agreement. Expressed opposition to FDA and PTO collaboration activities that would undermine IP rights. Hosted USPTO officials, Linda Horner, Andrea Grossman, and Zachariah Lucas at a Biocom California meeting on IP issues Advocated against policies that would negatively impact technology transfer programs at universities

Advocated for increased discretionary funding for HHS appropriations, including NIH, NCATS, CDC, BARDA, SNS Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for the VA appropriations, including the National Pharmacogenomic Program Advocated for increased discretionary funding for all federally funded scientific research institutions

Advocated for the protection of Intellectual Property rights Advocated for the protection of the Bayh-Dole Act and against using march-in provisions to control drug pricing Expressed opposition to the proposals waiving IP protections for covid-19 vaccines, diagnostics, and treatments under the TRIPS agreement. Expressed opposition to FDA and PTO collaboration activities that would undermine IP rights.

Advocated for permanent adoption of the telehealth flexibilities created during the COVID-19 public health emergency Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for California to be selected as an ARPA-H Hub. Held a reception for Members, including Reps. Duarte, Barragan, Correa, Lofgren, and Peters

Advocated for permanent adoption of the telehealth flexibilities created during the COVID-19 public health emergency Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for California to be selected as an ARPA-H Hub. Held a meet and greet with Reps. Peters, Valadao, Mullin, and Kiley on health issues Held a roundtable with FDA Digital Health Center of Excellence Director, Troy Tazbaz, on health issues

Advocated to reverse a tax provision preventing businesses from deducting their R&D expenses in the same year they were incurred

Advocated for passage of FDA policy legislation Advocated for increased use of digital health technologies Advocated for permanent adoption of the telehealth flexibilities created during the COVID-19 public health emergency Advocated against the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Held a roundtable event with Representative Young Kim on health issues

Advocated for the protection of Intellectual Property rights Advocated for the protection of the Bayh-Dole Act and against using march-in provisions to control drug pricing Expressed opposition to the proposals waiving IP protections for covid-19 vaccines, diagnostics, and treatments under the TRIPS agreement.

Advocated to reverse a tax provision preventing businesses from deducting their R&D expenses in the same year they were incurred

Advocated for passage of FDA User Fee legislation Advocated for legislation that would support greater use of genetic sequencing technologies Advocated for increased utilization and uptake of digital health technologies in health care Advocated for permanent adoption of the telehealth flexibilities created during the COVID-19 public health emergency Advocated against the drug pricing provisions of the Inflation Reduction Act Cohosted a Congressional briefing on Anti-microbial resistance Advocated for public health considerations in federal privacy legislation

Advocated for passage of FDA User Fee legislation Advocated against CMS National Coverage Decision on Amyloid-directed Monoclonal Antibodies for the Treatment of Alzheimers Disease Advocated for legislation that would support greater use of genetic sequencing technologies Advocated for increased utilization and uptake of digital health technologies in health care Advocated for permanent adoption of the telehealth flexibilities created during the COVID-19 public health emergency Held a Roundtable with Rep. Lou Correa on health issues, including new drugs and manufacturing

Advocated for increased discretionary funding for HHS appropriations, including NIH, NCATS, CDC, BARDA, SNS Advocated for increased discretionary funding for FDA appropriations, including CBER Advocated for increased discretionary funding for the VA appropriations, including the National Pharmacogenomic Program Advocated for increased discretionary funding for all federally funded scientific research institutions

Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products

Advocated for increased discretionary funding for R&D at government research institutions

Advocated for the protection of Intellectual Property rights Advocated for protection of the Bayh-Dole Act and against using march-in provisions to control drug pricing Expressed opposition to the Administration's decision to support waiving IP protections for covid-19 vaccines under the TRIPS agreement.

Urged the Department of Commerce to ensure the availability of semiconductor chips for the medical device industry.

Advocated against drug pricing legislation HR3, as a stand-alone bill and as a provision in the FY2022 reconciliation package. Advocated for antimicrobial resistance legislation. Supported the Medicare Coverage Innovation Pathway at CMS and expressed concerns with its withdrawal Submitted comments to FDA on cell and gene therapy early-stage clinical trials Hosted a legislative roundtable with Rep. Garcia to discuss the life science industry Hosted a legislative roundtable with Rep. Obernolte to discuss the life science industry Hosted an executive roundtable with CDRH to discuss the digital health center of excellence Hosted an executive roundtable with OSTP to discuss health care and life science priorities and initiatives

Advocated against drug pricing legislation HR3, as a stand-alone bill and as a provision in the FY2022 reconciliation package. Submitted comments on the Cures 2.0 draft legislation Advocated for antimicrobial resistance legislation

Expressed concerns with tax provisions in the FY2022 reconciliation bill, including raising the corporate tax rate and limiting the orphan drug tax credit

Expressed importance of intellectual property protections for the life science industry. Expressed opposition to the Administration's decision to support waiving IP protections for covid-19 vaccines under the TRIPS agreement.

Expressed importance of intellectual property protections for the life science industry. Expressed opposition to the Administration's decision to support waiving IP protections for covid-19 vaccines under the TRIPS agreement.

Advocated against HR3 via individual meetings with congressional offices and hosting a webinar for legislative staff on HR3 and patient access.

Expressed importance of intellectual property protections for the life science industry

Provided information on industry's response regarding the covid-19 pandemic Advocated against international reference pricing policies, including most favored nation and HR3 Presented new data from Vital Transformation on the impact of HR3 Hosted a webinar on international reference pricing Hosted a roundtable with Rep. Sara Jacobs Advocated in favor of CMS's MCIT coverage pathway for devices designated as breakthrough by the FDA Advocated against CMS's rule to waive protections for protected classes of drugs

Expressed support for the Bayh-Dole Act, as part of the law's 40th anniversary campaign. Expressed concerns about the misuse of "march-in rights" and compulsory licenses. Expressed support for PTAB protections.

Sent information to House and Senate staff about the life science's industry response to covid-19 Expressed strong concerns about executive orders and rules on most-favored nation and importation Hosted a legislative roundtable with Rep. Scott Peters Hosted a legislative roundtable with Rep. Harley Rouda Hosted a legislative roundtable with Rep. Ami Bera Expressed support for the coverage of home infusion of Medicare Part B drugs during the covid-19 pandemic. Expressed our position on domesticating the US drug supply chain Expressed our position on value-based agreements, line extensions and copay accumulator programs Expressed support for expanding telehealth services Expressed support for policies that encourage the use and development of novel antibiotics to fight anti-microbial resistance (AMR)

Advocated for additional funding for NIH, FDA, CDC and BARDA in FY2021 appropriations and coronavirus supplemental legislation.

Sent information to House and Senate staff about the life science's industry response to covid-19 Expressed strong concerns about executive orders on most-favored nation and importation Hosted a congressional webinar "Incentivizing R&D during a pandemic" Hosted a congressional webinar "The Use of Genomics in Response to the Pandemic" Advocated for the reauthorization of the Rare Pediatric Disease Priority Review Voucher Program Expressed support for the coverage of home infusion of Medicare Part B drugs during the covid-19 pandemic. Expressed our position on domesticating the US drug supply chain Expressed our position on value-based agreements and copay accumulator programs Expressed support for expanding telehealth services Expressed support for policies that encourage the use and development of novel antibiotics to fight anti-microbial resistance (AMR)

Advocated for additional funding for the Paycheck Protection Program (PPP), which had run out of funding Urged the US Treasury Department and SBA to clarify that small businesses with equity investors will be eligible for the small business loan program created by the CARES Act.

Expressed concerns with proposals that would restrict visas for international students, researchers and faculty as the country reopens

Advocated for targeted and temporary liability protections for life science organizations

Advocated for targeted and temporary liability protections for life science organizations

Expressed support for the Bayh-Dole Act, as part of the law's 40th anniversary campaign

Advocated for additional funding for the Paycheck Protection Program (PPP), which had run out of funding Urged the US Treasury Department and SBA to clarify that small businesses with equity investors will be eligible for the small business loan program created by the CARES Act.

Expressed support for provisions in the CARES Act that would support small businesses impacted by the covid-19 crisis (small business loans and grants, paycheck protection, NOL losses) Urged the US Treasury Department and SBA to clarify that small businesses with equity investors will be eligible for the small business loan program created by the CARES Act.

Expressed disappointment over the removal of data exclusivity protections in the USMCA. Expressed concerns regarding a possible "BuyAmerican" executive order, which could delay the development of COVID-19 vaccines, therapeutics and diagnostics, and worsen shortages of critically-needed medicines if the life science sector isn't exempt.

Advocated against HR3, the Lower Drug Costs Now Act of 2019, because of the negative impact it would have on innovation. Co-commissioned a joint report by Vital Transformation on the impact of HR3 on California.

Advocated to permanently repeal the medical device tax.

Expressed concerns after the 10 years of data exclusivities for biologics provision was removed from the United States-Mexico-Canada Agreement

Opposed legislation and policies that would undermine the US patent system, including "compulsory licenses"

Advocated for additional funding for NIH and FDA in FY2020 appropriations.

Advocated in favor of the USMCA.

Advocated for legislation to permanently repeal the medical device tax.

Opposed legislation and policies that would undermine the US patent system, including "compulsory licenses"

Advocated for additional funding for NIH and FDA in FY2020 appropriations.

Opposed legislation and policies that would undermine the US patent system, including "compulsory licenses" Hosted a roundtable with USPTO Director, Andrei Iancu Hosted a meeting with USPTO Director of Technology Center 3600, Tariq Hafiz

Held an advocacy fly-in to discuss the importance of digital health technologies, including funding, FDA and ONC regulations, reimbursement, and privacy and security considerations. Discussed drug pricing policies and their impact on innovation, including generic competition, reference pricing, price transparency, Medicare negotiation, protected classes, PBM rebates, and 340B reform. Advocated for the reauthorization of PAHPA.

Lobbied in opposition to "compulsory licenses" policies Advocated for reforms of IPR proceedings at the PTAB, including support of the STRONGER Patents Act

Supported the reauthorization of PAHPA Expressed concerns with step therapy policy, reference pricing, changes to Medicare Part B, and changes to the Part D protected classes Discussed how the life science community can help address the opioid crisis Advocated for reforms of the 340B drug program

Advocated for the suspension of the medical device tax.

Supported mandatory funding for the Energy Title in the Farm Bill.

Supported the reauthorization of PAHPA Expressed concerns with step therapy policy, changes to Medicare Part B, and changes to the Part D protected classes Expressed support for banning "gag clauses" in contract with pharmacists Discussed how the life science community can help address the opioid crisis Advocated for reforms of the 340B drug program

Advocated for the suspension of the medical device tax.

Supported mandatory funding for the Energy Title in the Farm Bill.

Co-hosted a Life Science Reception Hosted a congressional briefing supporting the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) Discussed how the life science community can help address the opioid crisis Supported expanded coverage of whole-genome sequencing Advocated for enhancements of the 340B drug program Expressed concerns over the establishment of a private litigation mechanism in the CREATES Act

Voiced opposition to tariffs on medical devices

Advocated for increased funding for NIH and FDA in FY2018 omnibus.

Advocated for the suspension of the medical device tax.

Hosted an advocacy fly-in about regenerative medicine Discussed how the life science community can help address the opioid crisis Supported expanded coverage of whole-genome sequencing Advocated for enhancements of the 340B drug program

Advocated for repeal of the medical device tax. Advocated for lower corporate tax rate and territorial tax system as part of tax reform. Advocated for protection of the orphan drug tax credit and state and local tax deductions, as part of tax reform.

Advocated for increased funding for NIH and FDA.

Advocated for the repeal of IPAB

Advocated for increased funding for NIH and FDA.

Advocated for the protection of 12 years of data exclusivities for biologics in NAFTA

Hosted a congressional briefing on oncology and genomics Advocated for the repeal of IPAB Advocated for the repeal of the medical device tax

Advocated for a clean re-authorization of FDA user fee agreements. Organized a DC fly-in to discuss oncology issues Co-hosted a congressional briefing on drug cost and value Co-hosted a life science reception

Discussed Biocom 2017 economic impact report and statewide expansion

Advocated for increased funding for NIH and FDA. Co-hosted a congressional briefing on NIH and FDA funding

Advocated for increased funding for NIH and FDA.

Discussed R&D tax credits

Advocated for a clean re-authorization of FDA user fee agreements.

Urged legislators to support the 21st Century Cures Act.

Asked for increased NIH funding; Participated in Rally for Medical Research Urged Congress to pass continuing resolution, that includes emergency funding for Zika

Expressed support for 21st century cures legislation and Senate biomedical bills.

Urged Congress to support GMO labeling legislation.

Asked Congress to prioritize the use of telehealth and remote patient monitoring technologies. Hosted a Precision Medicine Briefing to educate regulators and legislators about precision medicine. Expressed support for Senate biomedical initiative. Hosted Congressional Briefing on Value of Biomedical Innovation. Hosted life science reception on Capitol Hill.

Asked for increased NIH funding.

Asked for increased NIH funding.

Asked Congress to prioritize the use of telehealth and remote patient monitoring technologies. Organized a Precision Medicine Fly-In to educate regulators and legislators about precision medicine. Urged the Senate HELP Committee to provide mandatory funding for the NIH in its biomedical initiative. Raised concerns regarding CMS' Part B Demo.

Asked Congress to prioritize the use of emerging telehealth and remote patient monitoring technologies. Organized a Congressional briefing on digital health in the House and the Senate. Organized a Capitol Hill Reception in the House. Promoted the creation of the Congressional Life Science Caucus.

Advocated for 12 years of data exclusivities for biologics in the TPP agreement.

Expressed support for the repeal of the medical device tax. Urged Congress to pass the tax extenders package.

Raised concerns with H.R.9, the Innovation Act, and asked Members to oppose the bill. Advocated for a Hatch-Waxman/BPCIA exemption from IPR proceedings.

Asked for increased NIH funding. Asked Congress to pass legislation to fund the federal government in FY2016.

Asked to vote for HR6, the 21st Century Cures Act.

Urged Members to support Trade Promotion Authority (TPA) legislation.

Raised concerns with H.R.9, the Innovation Act and asked Members to oppose the bill. Expressed support for S.632, the Strong Patents Act and H.R.2045, the Trol Act.

Asked to support additional funding for NIH, FDA, and BARDA. Asked to support the FDA SOS Act, which would exempt FDA user fees from sequestration.

Expressed support for Medicare Part B and D and discussed patients' access to medicines. Discussed legislative proposals in the 21st Century Cures Initiative. Submitted comments to the Energy & Commerce Committee regarding 21st Century Cures. Discussed SBIR/STTR programs and current initiatives at the NIH.

Voiced support for a repeal of the medical device tax.

Asked to support additional funding for NIH, FDA, and BARDA. Asked to support the FDA SOS Act, which would exempt FDA user fees from sequestration.

Asked for increased funding for NIH, FDA, and biorenewable programs.

Asked to reauthorize the tax extenders. Asked to repeal the medical device tax.

Discussed 21st Century Cures proposals. Organized a Fly-In to discuss the digital health landscape, including regulation, reimbursement, data privacy and ownership, electronic health records (EHRs) and patient-generated health data (PGHD).

Presented our CA economic impact report.

Raised concerns with Senate patent litigation bill and lobbied in support of House demand letter bill.

Asked for increased funding of FDA, NIH, and bioenergy programs.

Presented our economic impact report

Asked to oppose cuts/rebates to Medicare Part B/D

Asked to support biorenewables/biofuels programs

Asked to support the farm bill Discussed USDA energy programs Discussed DOD energy programs

Expressed concerns with Senate legislation on patent litigation reform

Asked to support the omnibus appropriations bill Asked to support additional funding for FDA, NIH Asked to exempt FDA user fees from sequestration

Voiced support for mandatory funding of the Energy Title of the Farm Bill Voiced support for renewable chemicals parity Voice support for the Renewable Fuel Standard (RFS)

Asked to oppose H.R. 3309 and similar bills

Voiced support for track & trace provisions of H.R. 3204 Asked to oppose cuts to Medicare Part B and D

Sent letter regarding new SEC rule on angel investors

Voiced support for the Energy Title of the Farm Bill Voiced support for renewable chemicals parity Discussed renewable energy policies

Presented our 2014 Economic Impact Report

Asked that the sequestration of user fees be reversed Asked for adequate funding of FDA and NIH in FY2014 (no further cuts) Asked to oppose cuts to Medicare Part B

Asked to support a national drug track and trace system, with strong state pre-emption requirements Organized briefing on the value of medical innovation

Voiced support for mandatory funding of the Energy Title in the Farm Bill Voiced support for renewable chemicals eligibility in the Farm Bill Asked to oppose GE food labeling legislation

Voiced opposition to Medicare Part D drug rebates.

Voiced support for the Energy Title in the Farm Bill.

Voiced opposition to sequestration. Voiced support for funding of NIH, FDA, Medicare Part B, and BARDA.